Table 1.

Anakoinosis: designing evolutionary processes in tumor tissues and exploiting and operationalizing their scope with cellular therapies in situ

	Cellular therapy in situ Anakoinosis: Designing evolutionary processes in tumor tissues and exploiting and operationalizing their scope
Drug repurposing for communication design	Anakoinosis promoting therapeutic tools: ‘Top down’ strategies
	Dual transcriptional modulation	Metronomic low-dose chemotherapy	Classic targeted therapy
Communication derived tools for evolving tumor systems	Evolving tumor systems • Targets are ubiquitously distributed among tumor, stroma and organ cells; • Stimulating, not blocking	Modulation of • Angiogenesis, immune response, inflamation; • Cell type dependent biomodulatory activity	Drug repurposing • Novel activity profile of targeted therapies in the biomodulatory context; • Pleiotropic novel activities
• Targeting rationalizations of cancer hallmarks • Targeting modular events • Targeting the ‘metabolism’ of evolutionary processes • Targetring the holistic communicative context by implementation of non-normative boundary conditions	• Pioglitazoine (Actos) 45 mg p.o. daily • All-trans retenoic acid 45 mg2 p.o. daily • Interferon alpha 3MU s.c. three times a week Pioglitazone (Actos) 60 mg p.o. daily • Pioglitazone (Actos) 60 mg p.o. daily Dexamethasone 0.5 to 1.0 mg daily	• Treosulfan 250 mg twice daily • Trofosfamide 50 mg thrice daily • Capecitabine 1 g twice daily • 5-azacytidine 75 mg absolute 7 days, every 4 weeks	• Low-dose lenalidomide (after lenalidomide failure) 15 mg p.o. daily • Imatinib 400 mg p.o. daily • mTor inhibitor (in Hodgkin lymphoma, everolimus, serum level 15 ng/ml; in multivisceral Langerhans cell histiocytosis, temsirolimus weight-adapted in child) • COX-2 inhibitor etoricoxib 60 mg p.o. daily or rofecoxib 25 mg daily